Macaques develop short-term immunity to SARS-CoV-2
Researchers experimenting on macaques reveal they were protected against reinfection up to a month after the initial exposure to SARS-CoV-2.
List view / Grid view
Researchers experimenting on macaques reveal they were protected against reinfection up to a month after the initial exposure to SARS-CoV-2.
Researchers have suggested that the MMR live attenuated vaccine could be used to provide non-specific protection to patients against sepsis associated with COVID-19.
Researchers have analysed the SARS-CoV-2 proteome to reveal seven promising immunodominant epitopes that could aid in the development of a COVID-19 vaccine.
Researchers used computational tools to identify regions of the SARS-CoV-2 virus that could potentially provide a safe and long-term immune response.
Researchers in the US describe how they utilised previously published scientific literature to guide the design of their potential COVID-19 vaccine.
Researchers demonstrate that a subpopulation of circulating white blood cells can act as an early indicator of vaccine efficacy, with potential implications for COVID-19 drug development.
Macaques were protected against SARS-CoV-2 infection both after an initial infection and vaccination with a prototype vaccine, researchers suggest humans could respond similarly.
A detailed analysis of the body's immune response to COVID-19 has revealed that it can recognise SARS-CoV-2 in many ways, meaning vaccines can be used to stop the spread of the virus.
A vaccine currently in Phase I clinical trials was effective at inducing immune responses against SARS-CoV-2 in mice and rhesus macaques.
Dr Bernard Fox from Providence Cancer Institute explains how OncoSec’s CORVax12 vaccine works to potentially combat COVID-19.
Russian researchers have created a process for the development of mouse models for use in pre-clinical studies of COVID-19 treatments and vaccines.
A MERS vaccine, which uses RNA-based adjuvants, has demonstrated efficacy in non-human primates and is now being developed as a prophylactic for COVID-19.
Ali Shilatifard’s article explains how investment in institutes performing molecular research is essential, as it is the foundation for all attempts to combat COVID-19 and other future pandemics.
A total of 21 COVID-19 research projects have been granted funding by the UK government, including vaccine and therapeutic development.
Researchers have made the genome of the Nicotiana benthamiana plant, a commonly used bio-factory organism, public to aid in COVID-19 vaccine production.